90 related articles for article (PubMed ID: 1424519)
1. Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.
Brumfitt W; Hamilton-Miller JM
Diagn Microbiol Infect Dis; 1992; 15(7):621-5. PubMed ID: 1424519
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.
Barry AL
Antimicrob Agents Chemother; 1988 Jan; 32(1):150-2. PubMed ID: 3348606
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Zurenko GE; Yagi BH; Schaadt RD; Allison JW; Kilburn JO; Glickman SE; Hutchinson DK; Barbachyn MR; Brickner SJ
Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.
Mini E; Novelli A; Mazzei T; Periti P
Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):256-60. PubMed ID: 2523807
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.
Neu HC; Novelli A; Saha G; Chin NX
Antimicrob Agents Chemother; 1988 Apr; 32(4):580-3. PubMed ID: 3377467
[TBL] [Abstract][Full Text] [Related]
6. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
Wise R; Andrews JM; Boswell FJ; Ashby JP
J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
[TBL] [Abstract][Full Text] [Related]
7. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.
Slee AM; Wuonola MA; McRipley RJ; Zajac I; Zawada MJ; Bartholomew PT; Gregory WA; Forbes M
Antimicrob Agents Chemother; 1987 Nov; 31(11):1791-7. PubMed ID: 3435127
[TBL] [Abstract][Full Text] [Related]
8. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones.
Brumfitt W; Hamilton-Miller JM
J Antimicrob Chemother; 1988 Jun; 21(6):711-20. PubMed ID: 3137206
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antibacterial activity of novel (un)substituted benzotriazolyl oxazolidinone derivatives.
Dixit PP; Nair PS; Patil VJ; Jain S; Arora SK; Sinha N
Bioorg Med Chem Lett; 2005 Jun; 15(12):3002-5. PubMed ID: 15908210
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Jones RN; Johnson DM; Erwin ME
Antimicrob Agents Chemother; 1996 Mar; 40(3):720-6. PubMed ID: 8851600
[TBL] [Abstract][Full Text] [Related]
11. Novel tetrahydro-thieno pyridyl oxazolidinone: an antibacterial agent.
Lohray BB; Lohray VB; Srivastava BK; Kapadnis PB; Pandya P
Bioorg Med Chem; 2004 Sep; 12(17):4557-64. PubMed ID: 15358283
[TBL] [Abstract][Full Text] [Related]
12. Carbon-carbon-linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria.
Lee CS; Allwine DA; Barbachyn MR; Grega KC; Dolak LA; Ford CW; Jensen RM; Seest EP; Hamel JC; Schaadt RD; Stapert D; Yagi BH; Zurenko GE; Genin MJ
Bioorg Med Chem; 2001 Dec; 9(12):3243-53. PubMed ID: 11711300
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of macrolides against gram-positive aerobes, Haemophilus influenzae, Moraxella catarrhalis and Bacteroides fragilis in Taiwan.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Apr; 62(4):230-5. PubMed ID: 10367484
[TBL] [Abstract][Full Text] [Related]
14. In vitro studies with Bay V 3522, a new oral cephalosporin.
Thomson KS; Sanders CC; Sanders WE
Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
16. Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
Genin MJ; Allwine DA; Anderson DJ; Barbachyn MR; Emmert DE; Garmon SA; Graber DR; Grega KC; Hester JB; Hutchinson DK; Morris J; Reischer RJ; Ford CW; Zurenko GE; Hamel JC; Schaadt RD; Stapert D; Yagi BH
J Med Chem; 2000 Mar; 43(5):953-70. PubMed ID: 10715160
[TBL] [Abstract][Full Text] [Related]
17. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
Sultan T; Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
